ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)
Portfolio Pulse from
ALK has entered a strategic license agreement with ARS Pharmaceuticals for the global rights to neffy®, an adrenaline nasal spray for anaphylaxis, excluding certain countries. This aligns with ALK's Allergy+ strategy and supports its financial goals.
November 09, 2024 | 10:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ARS Pharmaceuticals has licensed global rights (excluding certain countries) for its neffy® nasal spray to ALK, potentially increasing its market reach and revenue.
The licensing agreement with ALK allows ARS Pharma to expand the reach of its neffy® nasal spray, potentially increasing its market presence and revenue. This strategic move aligns with ARS Pharma's growth objectives.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80